Business Context and Reporting Period
This Form 6-K filing by Zhengye Biotechnology Holding Ltd (ZYBT) covers the month of August 2026. The report addresses the Company's status regarding Nasdaq listing requirements, specifically the Minimum Bid Price Rule.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory compliance update rather than a financial results report.
Material Changes
- Regulatory Status: The Company previously received a notification on May 29, 2026, regarding non-compliance with Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 for 30 consecutive business days.
- Compliance Achievement: From July 20, 2026, to August 4, 2026, the closing bid price of Class A ordinary shares remained at or above $1.00 per share.
- Outcome: On August 5, 2026, Nasdaq issued a Compliance Letter confirming the Company regained compliance. The Company remains listed on The Nasdaq Capital Market.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operations, or new risk factors. The primary contingency addressed was the potential delisting risk associated with the Minimum Bid Price Rule, which has been resolved as of the filing date.
Investor Verification Checklist
- Verify the current trading price of ZYBT Class A ordinary shares to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the Company's continued listing status on The Nasdaq Capital Market.
- Review the attached press release (Exhibit 99.1) for any additional details on the compliance confirmation.